1. Hypercholesterolaemia

   • Dag S. Thelle

   Introduction 26 October 2012 Pages: 1 - 8

2. Effects of HMG CoA Reductase Inhibitors on Cholesterol Synthesis

   • Alfred W. Alberts

   Section 1: Mechanism of Action 26 October 2012 Pages: 9 - 17

3. Comparison of Plasma Profiles of Lovastatin (Mevinolin), Simvastatin (Epistatin) and Pravastatin (Eptastatin) in the Dog

   • R. J. Stubbs
   • M. S. Schwartz
   • W. F. Bayne

   Section 1: Mechanism of Action 26 October 2012 Pages: 18 - 28

4. Inhibition of Dietary Cholesterol Absorption During Lovastatin (Mevinolin) Treatment

   • T. A. Miettinen
   • M. J. Tikkanen
   • J.-P. Ojala

   Section 1: Mechanism of Action 26 October 2012 Pages: 29 - 35

5. Discussion: Section 1

   Section 1: Mechanism of Action 26 October 2012 Pages: 36 - 36

6. Enhanced Hepatic Uptake of Low Density Lipoprotein by Lovastatin (Mevinolin) in Man

   • Markku J. Savolainen
   • Kari Kervinen
   • Antero Kesäniemi

   Section 2: Efficacy of HMG CoA Reductase Inhibitors 26 October 2012 Pages: 37 - 39

7. Switch from Gemfibrozil to Lovastatin (Mevinolin) Therapy in Patients with Primary Hypercholesterolaemia

   • Jukka-Pekka Ojala
   • E. Helve
   • J. Viikari

   Section 2: Efficacy of HMG CoA Reductase Inhibitors 26 October 2012 Pages: 40 - 47

8. Effect of Simvastatin Therapy on Apolipoproteins

   • W. F. Riesen
   • U. Keller
   • F. W. Rentier

   Section 2: Efficacy of HMG CoA Reductase Inhibitors 26 October 2012 Pages: 48 - 52

9. Efficacy and Tolerability of Simvastatin (Epistatin) in the Elderly

   • J. Findlay Walker
   • Rene A. Pingeon
   • Debora A. Shapiro

   Section 2: Efficacy of HMG CoA Reductase Inhibitors 26 October 2012 Pages: 53 - 56

10. Discussion: Section 2

    Section 2: Efficacy of HMG CoA Reductase Inhibitors 26 October 2012 Pages: 57 - 57

11. Long Term Clinical Tolerance of Lovastatin (Mevinolin) and Simvastatin (Epistatin)

    • David W. Bilheimer

    Section 3: Long Term Clinical Tolerability 26 October 2012 Pages: 58 - 67

12. Indications for the Use of HMG CoA Reductase Inhibitors

    • Kurt Widhalm

    Section 3: Long Term Clinical Tolerability 26 October 2012 Pages: 68 - 73

13. Mechanistic and Clinical Rationale for the Use of HMG CoA Reductase Inhibitors in Prevention of Atherosclerosis

    • Gert M. Kostner

    Section 3: Long Term Clinical Tolerability 26 October 2012 Pages: 74 - 75

14. Discussion: Section 3

    Section 3: Long Term Clinical Tolerability 26 October 2012 Pages: 76 - 76